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doi:10.1016/j.ijid.2007.04.005Figure 1 Dissemination of visceral leishmaniasis to the skin.Gastric and cutaneous dissemination of visceral
leishmaniasis in a patient with advanced HIV
Visceral leishmaniasis (VL) is a well-recognized opportunistic
infection in patients with HIV-1 infection. Several reports
indicate a rising trend in VL/HIV co-infection. Themajority of
HIV/Leishmania co-infected cases show classic features of
VL. Atypical features such as dissemination to the gastro-
intestinal tract and to the skin may also occur.
We describe herein a patient with advanced HIV-1 infec-
tion residing in a non-endemic area for leishmaniasis. The
diagnosis of HIV had been made 4 years prior to this admis-
sion. Unfortunately, the Centers for Disease Control and
Prevention (CDC) stage at the time of diagnosis was not
known. He presented with atypical features of visceral
leishmaniasis. In particular, the patient had dissemination
to the esophagus, the stomach, and to the skin.
A 50-year-old Omani male presented with progressive
dysphagia, diarrhea with vague abdominal pain, severe anor-
exia, and weight loss of 20 kg over 6 months. A history of
intermittent episodes of high-grade fever, chills, night
sweats, weakness, and occasional headaches was elicited.
The patient had also noticed the appearance of multiple
pigmented plaques over his face and neck during the same
period. He had lost the vision in his left eye 3 months earlier.
The patient denied any history of travel outside Oman.
Examination showed a sick looking patient with severe
wasting and marked pallor. He was febrile and had neck
stiffness with intact sensorium and no focal deficit. Skin
examination revealed multiple pigmented plaques of 3 1 cm over the right mandible and left base of the neck
(Figure 1). Similar lesions were seen over the hard palate.
Multiple enlarged cervical lymph nodes were noted with no
hepatosplenomegaly. The patient had no light perception in
the left eye; visual acuity in the right eye was limited to
finger counting. Fundoscopy showed changes consistent with
cytomegalovirus (CMV) retinitis in both eyes.
Laboratory findings were as follows: full blood count
revealed anemia (Hb 9.6 g/dl), leukopenia (white blood cell
count: 2.97  109/l), and a normal platelet count (276 
109/l). ELISA and Western blot for HIV-1 was positive. The
HIV-1 viral load was 480 000 RNA copies/ml, with an absolute
CD4 count of 3.0/ml, CD4/CD8 ratio of 0.005:1.
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Figure 4 Peripheral blood smear with numerous Leishmania
donovani bodies.Esogastroduodenoscopy showed a large distal esophageal
ulcer and inflamed gastric mucosa, which were biopsied.
Pigmented skin plaques were also biopsied. Peripheral blood,
skin plaque, and gastric mucosa all showed large numbers of
Leishmania amastigotes (Figures 2—4). In addition, examina-
tion of the gastric mucosa showed evidence of concurrent
CMV infection (Figure 2). Cryptococcal antigen was positive
and culture of cerebrospinal fluid grew Cryptococcus neofor-
mans. The patient received liposomal amphotericin (5 mg/kg
daily) for 2 weeks and this was followed by fluconazole
400 mg IV daily for 10 weeks (continuation therapy for cryp-
tococcal meningitis). IV Ganciclovir at a dose of 5 mg/kg
twice daily was also initiated. Highly active antiretroviral
therapy (HAART) was not initiated during this period.
HIV testing was carried out using the AxSYM1 HIV Ag/Ab
Combo (Abbott Laboratories, Wiesbaden, Germany). Serolo-
gical testing for Leishmania donovaniwas carried out using an
indirect hemagglutination test (Cellognost, Dade Behring,
Marburg, Germany). This serologic test detects Leishmania
donovani-specific human antibodies.
Our patient had a severe HIV-1 infection with cryptococcal
meningitis and CMV gastritis, and was found to have visceral
leishmaniasis. According to the Ministry of Health of Oman,Figure 3 Gastric mucosa with numerous Leishmania donovani
bodies; H&E.
Figure 2 Biopsy of gastric mucosa showing an epithelial cell
containing a large cytomegalovirus inclusion body; H&E.the first case of HIV was reported in 1984. From 1984 to 2005,
1446 HIV cases were recorded, corresponding to an incidence
rate of 3.9 per 100 000.1 Visceral and cutaneous leishmaniasis
occur sporadically in Oman with fewer than 50 cases per
year.2 The most common causative agent of leishmaniasis in
Oman is Leishmania infantum and this may explain why our
serological test was negative.2 Leishmania/HIV co-infection
is emerging as a serious new disease pattern and is becoming
increasingly frequent. The prevalence of VL in AIDS patients
is more than 100 times greater than in immunocompetent
hosts.3 The majority of VL cases in HIV-positive patients
appear in the advanced stages of the disease, and in addition
other concomitant opportunistic infections are diagnosed in
more than 42% of affected patients.4,5
The clinical diagnosis of VL in AIDS patients is difficult as
patients present without the classical triad of fever, hepa-
tosplenomegaly, and pancytopenia, as was the case in our
patient who presented with gastrointestinal symptoms and
fever.3 Patients with VL/HIV co-infection have Leishmania in
unusual locations in 10—30% of those infected.6 Gastrointest-
inal symptoms are among themost frequent complaints.7 The
most common site of involvement is the jejunum,8 while
clinical esophageal involvement is relatively rare. To our
knowledge, only 10 cases of Leishmania esophagitis have
been reported in this situation.9 Mucocutaneous involvement
is another uncommon occurrence seen in 2—3% of affected
persons. Our patient has dissemination of Leishmania to the
skin and the stomach with probable involvement of the hard
palate on the basis of themorphologic similarity of the palate
lesion to those of the biopsied skin plaques. Dissemination to
multiple sites as illustrated is probably a reflection of the
severe degree of CD4 lymphopenia.
Direct observation of amastigotes in peripheral blood
preparations is considered a simple, rapid, non-invasive
method that permits diagnosis in infected individuals.10
However, amastigotes in the peripheral blood are seen in
only 50% of co-infected patients.5,11 Leishmania serology is
only positive in 40—50% of VL/HIV co-infected cases. The
percentage is inversely proportional to CD4 count. Serology
was negative in our patient, whichmay be due to the very low
CD4 count, or to the fact that the assay is only designed to
detect Leishmania donovani species, which is not common in
Correspondence 113Oman. Amastigotes were identified in peripheral blood in our
patient.
Treatment of VL with conventional drugs gives poor
results in HIV patients. Relapse is common after one year
of treatment.5,12 Our patient was treated with liposomal
amphotericin B for 14 days. He showed some initial
improvement in his symptoms — the fever settled and his
appetite improved during his 16-day hospitalization. The
skin lesions were unchanged during this period. Unfortu-
nately he defaulted from the outpatient clinic and was lost
to follow-up. It later came to our knowledge that the
patient had died in a peripheral hospital from a fulminant
sepsis.
To our knowledge this is the first case of VL/HIV co-
infection reported from Oman with cutaneous and gastric
dissemination of Leishmania in addition to coexisting CMV
gastritis. This case illustrates unusual and rare manifesta-
tions of VL in the setting of advanced HIV concurrently with
two other opportunistic infections. The diagnosis was made
on examination of a peripheral blood film in the course of
investigation of this patient’s illness.
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